1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Filana Therapeutics, Inc.

Filana Therapeutics, Inc.

FLNA
Filana Therapeutics, Inc.US flagNASDAQ Global Market
1.01
USD
-0.01
- -
48.79MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6.4
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
4.91
-1.92
-2.16
-2.28
-1.82
-0.61
-0.27
-0.24
-0.82
-1.9
-2.32
-0.53
-1.88
-1.61
Free Cash Flow per Basic Share
-1.08
-1.49
-1.41
-1.89
-1.26
-0.45
-0.15
-0.21
-1.33
-2
-1.97
-2.53
-0.68
-0.63
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-16.18
-18.01
-19.98
-22.31
-24.08
-15.35
-9.68
-6.7
-5.26
-7.05
-9.08
-8.74
-10.27
-10.48
Tangible Book Value per Share
7.51
6.19
4.49
2.86
1.48
1.84
1.27
3.53
6.42
5.64
3.27
3.14
1.54
1.41
Basic Weighted Avg Shares
6
6
7
7
7
11
17
26
39
40
42
46
48
48
Sales/Revenue/Turnover
41
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
76.28
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
1
1
2
1
1
1
Net Income, GAAP
32
-12
-14
-15
-12
-7
-5
-6
-32
-76
-97
-24
-91
-78
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
76.71
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
48
40
29
18
10
20
22
92
232
204
115
125
54
48
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
48
40
29
19
10
20
22
92
254
228
137
146
74
68
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
48
48
48
Market Capitalization
- -
- -
82

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
109
98
88
Cash, Cash Equivalents & STI
106
96
87
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
48
44
40
Payables & Accruals
47
42
40
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
43.02%
16.5%
-48.94%
Free Cash Flow
92.32%
179.93%
-71.95%
Net Income, GAAP
72.06%
154.6%
273.73%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.58
0.13
-0.58
-0.57
-0.53
2025
-0.48
-0.92
-0.22
-0.26
-1.88
2026
-0.21
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Richard Jon Barry
Full Time Employees
20
Sector
Healthcare
Industry
Biotechnology
Address
6801 N. Capital of Texas Highway Austin TX United States of America 78731
IPO Date
Jul 14, 2000
CIK
0001069530
Website
filanatx.com
Similar Companies
Aerpio Pharmaceuticals, Inc. (ARPO)
PepGen Inc. (PEPG)
Polydex Pharmaceuticals Limited (POLXF)
Ergomed plc (2EM.DE)
Celcuity Inc. (CELC)
Medicenna Therapeutics Corp. (MDNA)
Business
Filana Therapeutics, Inc. is a clinical‑stage biotechnology company focused on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system disorders, including tuberous sclerosis complex (TSC)–related epilepsy, and other diseases associated with filamin A dysregulation. The company aims to address unmet medical needs by advancing its lead candidate simufilam, a proprietary small molecule oral therapy, through late‑stage development; it is also pursuing diagnostic and biomarker programs such as SavaDx to detect Alzheimer's disease. Filana Therapeutics operates from its headquarters in Austin, Texas, and has ongoing research and development collaborations and clinical activities aimed at expanding its portfolio and validating filamin A–targeted approaches across CNS indications. Founded in 1998, the company previously operated under a different corporate name and branding and recently rebranded to reflect its strategic emphasis on filamin A–related therapeutics and CNS disease modulation. Filana Therapeutics’ product and service scope includes: development of small molecule therapies targeting filamin A; clinical trial management and execution; biomarker and diagnostic asset development; strategic partnerships and collaborations for drug development, regulatory submission support, and translational research; and ongoing monitoring of regulatory interactions, including responses to agency inquiries, to advance its clinical programs and optimize capital efficiency. The company’s geographic footprint centers on the United States with R&D activities and trials conducted via affiliated sites and collaborations, supported by a network of scientific and clinical advisors and partner organizations to advance its CNS disorder pipeline. Filana Therapeutics’ business segments span therapeutic development, diagnostic asset exploration, and corporate partnerships, with a primary emphasis on CNS diseases tied to filamin A biology.

Company News

APIChatGPT

  • globenewswire.com

    Filana Therapeutics Reports Q1 2026 Financial Results and Business Update

  • globenewswire.com

    Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII

  • defenseworld.net

    Zevra Therapeutics (NASDAQ:ZVRA) versus Cassava Sciences (NASDAQ:FLNA) Head-To-Head Contrast